Trade Iovance Biotherapeutics - IOVA CFD

Iovance Biotherapeutics Company profile

About Iovance Biotherapeutics Inc

Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cell therapies as cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. It has developed a new, shorter manufacturing process for tumor infiltrating lymphocyte (TIL) known as Generation 2 (Gen 2), which yields a cryopreserved TIL product. Its lead product candidates include lifileucel for metastatic melanoma and metastatic cervical cancer, as well as LN-145 for metastatic non-small cell lung cancer (NSCLC). In addition, the Company is investigating the combinations of TIL therapy with immune checkpoint inhibitors (ICIs) in metastatic melanoma, cervical cancer (NSCLC), and head and neck squamous cell carcinoma (HNSCC). It is investigating peripheral blood lymphocyte (PBL) therapy for patients with refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Iovance Biotherapeutics Inc revenues was not reported. Net loss increased 32% to $342.3M. Higher net loss reflects Research and development - Balancing increase of 20% to $218.2M (expense), Research and development increase from $19.7M to $40.8M (expense), General & Administrative - Balancing increase of 40% to $54.7M (expense).

Equity composition

Common Stock $.00004 Par, 4/11, 1.8B auth., 70,683,349 issd. Insiders & Strategic holders own 32.66%. 4/10, 24-for-1 Stock split. The company changed its name from Freight Management Corp. to Genesis Biopharma, Inc. 09/13, 1-for-100 Reverse Stock split.